Abstract Number: 0783 • ACR Convergence 2022
Breakthrough SARS-CoV-2 Infections and Predicting Severe Outcomes During Rituximab Therapy in Autoimmune Rheumatic Diseases
Background/Purpose: There are concerns regarding the safety of rituximab (RTX) during the COVID-19 pandemic due its effect on humoral immunity. Data from registries during pre-vaccination…Abstract Number: 2027 • ACR Convergence 2022
Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome
Background/Purpose: Salivary gland involvement is a hallmark of disease in primary Sjögren's syndrome (pSS). This is reflected by the prominent role of a positive biopsy…Abstract Number: 1251 • ACR Convergence 2021
Serum B Cell Activating Factor Reflects Good EULAR Response to TNF Inhibition in Patients with Rheumatoid Arthritis
Background/Purpose: The latest breakthroughs in the pathophysiology of rheumatoid arthritis (RA) highlighted the activation of B cells as a trigger of the joint flare initiation…Abstract Number: 1301 • ACR Convergence 2021
Early Increase in Circulating Memory B Cells Portends Clinical Response to Treatment in Pooled Data from Three Phase III Trials of Belimumab
Background/Purpose: Belimumab blocks soluble B cell activating factor (BAFF) and is the only to date approved targeted treatment for systemic lupus erythematosus (SLE). Identification of…Abstract Number: 1303 • ACR Convergence 2021
Associations Between Early Changes in Circulating B Cell Subsets and Severe Flare in Systemic Lupus Erythematosus – Results from Three Phase III Trials of Belimumab
Background/Purpose: Belimumab is the only approved targeted treatment for systemic lupus erythematosus (SLE). Identification of early predictors of response or non-response to therapy is imperative…Abstract Number: 1429 • ACR Convergence 2021
ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Diseases
Background/Purpose: B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) are TNF superfamily members that bind TACI (transmembrane activator and CAML interactor), BCMA…Abstract Number: 0002 • ACR Convergence 2021
Salivary Sodium Levels in the Parotid Salivary Gland of SS Patients Suggest B-cell Mediated Epithelial Sodium Channel Disruption
Background/Purpose: Patients with Sjögren’s syndrome (SS) suffer from significantly reduced saliva production. Saliva is important for oral health. A careful of sodium, chloride, potassium and…Abstract Number: 1484 • ACR Convergence 2021
B Cell Intracellular IFNβ as a Unique Cellular Marker for the Development of Lupus Nephritis
Background/Purpose: Our laboratory previously demonstrated a strong association of B cell intracellular interferon beta (IFNβ) with the development of anti-Smith/ribonuclear protein (Sm/RNP), anti-DNA, and lupus…Abstract Number: 0004 • ACR Convergence 2021
Unappreciated Systemic Metabolic Functions of the Canonical B Cell Cytokines, BAFF and APRIL: Regulation of Lipolysis and Non-shivering Thermogenesis and Protection from Obesogenic Diet Induced Weight Gain
Background/Purpose: The impact of immune mediators on weight homeostasis and systemic metabolism remains underdefined. Interrogation of resistance to diet-induced obesity in mice lacking a negative…Abstract Number: 1490 • ACR Convergence 2021
Myeloid and B Cell Transcriptional Phenotypes Reveal Race Dependent Differences in Early Autoimmunity
Background/Purpose: Early immune events leading to clinical autoimmune disease are complex and the pathways involved remain incompletely defined. Anti-nuclear antibody (ANA) positivity is a feature…Abstract Number: 0006 • ACR Convergence 2021
Metabolic Characteristics of Age-related B Cells in Lupus-prone Mice and Effects on Follicular Helper T Cells
Background/Purpose: Since the description of age-associated B cells (ABC), there has been a growing interest in the role of these cells in autoimmunity. Evidence suggests…Abstract Number: 1502 • ACR Convergence 2021
Longitudinal Changes in B Cell Subsets in Patients in the Mesenchymal Stromal Cell Trial in Lupus: Analysis of the First Cohort
Background/Purpose: Recent advances allow expanded identification of B cell subtypes of pathogenic potential in lupus. Of particular interest are IgD- CD27- double negative (DN2) B…Abstract Number: 0008 • ACR Convergence 2021
Jo-1-Binding and Clonally-Expanded Memory B Cells Express Germline and Somatically-Mutated B Cell Receptors in Anti-tRNA Synthetase Syndrome Patients
Background/Purpose: Anti-tRNA synthetase syndrome (ARS) is a severe systemic autoimmune disease associated with myositis, interstitial lung disease, rash, and arthritis. ARS is associated with autoantibodies…Abstract Number: 1905 • ACR Convergence 2021
CD11c+ Expression Associates with IFN-λ Responsiveness in Human B Cells with Clinical Implications for SLE
Background/Purpose: Type I interferon (IFN), namely IFN- α, and B cell aberrations are long recognized in systemic lupus erythematosus (SLE) pathogenesis. Type I IFN receptor…Abstract Number: 0010 • ACR Convergence 2021
Relaxed Peripheral Tolerance Drives Broad de Novo Autoreactivity in Severe COVID-19
Background/Purpose: An emerging feature of COVID-19 is the identification of autoreactivity in patients with severe disease that may contribute to disease pathology, however the origins…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- Next Page »